StockData
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA) stock

KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.51+0.08 (+17.64%)

Close on Nov 18, 2026Market cap $17.07MP/E –Yield –

Pasithea Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Pasithea Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$23.96M. For fiscal 2025 it was -$20.86M. The highest annual figure on record is -$4.51M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$20.86M–
FY2024Dec 31, 2024-$14.25M–
FY2023Dec 31, 2023-$15.98M–
FY2022Dec 31, 2022-$12.59M–
FY2021Dec 31, 2021-$4.51M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.71M–
Q1 FY2026Mar 31, 2026-$4.88M–
Q4 FY2025Dec 31, 2025-$10.26M–
Q3 FY2025Sep 30, 2025-$3.11M–
Q2 FY2025Jun 30, 2025-$3.81M–
Q1 FY2025Mar 31, 2025-$3.68M–
Q4 FY2024Dec 31, 2024-$3.26M–
Q3 FY2024Sep 30, 2024-$3.00M–
Q2 FY2024Jun 30, 2024-$3.95M–
Q1 FY2024Mar 31, 2024-$4.04M–
Q4 FY2023Dec 31, 2023-$5.15M–
Q3 FY2023Sep 30, 2023-$3.79M–
Q2 FY2023Jun 30, 2023-$3.83M–
Q1 FY2023Mar 31, 2023-$3.21M–
Q4 FY2022Dec 31, 2022-$4.04M–
Q3 FY2022Sep 30, 2022-$3.86M–
Q2 FY2022Jun 30, 2022-$2.61M–
Q1 FY2022Mar 31, 2022-$2.08M–
Q4 FY2021Dec 31, 2021-$1.96M–
Q3 FY2021Sep 30, 2021-$1.27M–
Q2 FY2021Jun 30, 2021-$727.95K–
Q1 FY2021Mar 31, 2021-$549.61K–
Q3 FY2020Sep 30, 2020-$13.97K–

More Pasithea Therapeutics figures

See a number that looks wrong?